The crucial question: does adjuvant radiotherapy confer a survival benefit in pN1 oral squamous cell carcinoma (OSCC)? - A retrospective analysis
Oral and Maxillofacial Surgery · 2026
DOI: 10.1007/s10006-026-01654-1 ↗Kurz gefasst
Fachartikel in der Zeitschrift Oral and Maxillofacial Surgery, 2026. Verfasst von Maximilian Richter und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oral and Maxillofacial Surgery, Campus Virchow-Klinikum, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Be…. Hauptthemen laut MEDLINE: Mouth Neoplasms, Carcinoma, Squamous Cell. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Charité - Universitätsmedizin Berlin.
Abstract (Originalsprache)
Objective
Despite continuous research on the role of adjuvant therapy in the pN1 setting in Oral Squamous Cell Carcinoma (OSCC), clear recommendations for or against its use remain lacking. The objective of this study is to further strengthen the existing evidence base and support informed clinical decision-making. Materials and methods This retrospective analysis included all patients with primary pT1–2 pN1 OSCC without extracapsular spread who underwent surgical treatment at the Department of Oral and Maxillofacial Surgery, Charité – Universitätsmedizin Berlin. Survival analyses were performed using Kaplan–Meier methods and Cox regression models for the overall cohort as well as after propensity score matching (PSM).
Results
A total of 58 patients (male: 34 (58.6%), female: 24 (41.4%)) with a mean age of 63.6 years were included. In the overall cohort, there were no significant differences in overall survival (OS) or recurrence free survival (RFS) between patients treated with surgery alone and those who received adjuvant therapy ( p = 0.628; p = 0.244). In contrast, following PSM, adjuvant therapy was associated with a reduced risk of recurrence, as reflected by improved RFS (HR 0.21 (CI: 0.02–0.85, p = 0.029)).
Conclusion
In summary, our findings suggest an association between adjuvant therapy and improved RFS in patients with T1–2 pN1 OSCC, indicating a potential oncological benefit that should be considered in the context of individual clinical characteristics and balanced against potential treatment-related adverse effects.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Oral and Maxillofacial Surgery, Campus Virchow-Klinikum, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Augustenburger Platz 1, 13353…
- Department of Radiation Oncology and Radiotherapy, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Augustenburger Platz 1, 13353, Berlin, Germany.
Förderung
- Charité - Universitätsmedizin Berlin
Zitieren
APA
Richter, M., Tworek, A., Koerdt, S., Heiland, M., Knoedler, L., Zips, D., Beck, M., & Mrosk, F. (2026). The crucial question: does adjuvant radiotherapy confer a survival benefit in pN1 oral squamous cell carcinoma (OSCC)? - A retrospective analysis. Oral and Maxillofacial Surgery. https://doi.org/10.1007/s10006-026-01654-1
Vancouver
Richter M, Tworek A, Koerdt S, Heiland M, Knoedler L, Zips D, et al. The crucial question: does adjuvant radiotherapy confer a survival benefit in pN1 oral squamous cell carcinoma (OSCC)? - A retrospective analysis. Oral and Maxillofacial Surgery. 2026. doi:10.1007/s10006-026-01654-1
BibTeX
@article{Richter2026,
author = {Richter, Maximilian and Tworek, Aleksandra and Koerdt, Steffen and Heiland, Max and Knoedler, Leonard and Zips, Daniel and Beck, Marcus and Mrosk, Friedrich},
title = {The crucial question: does adjuvant radiotherapy confer a survival benefit in pN1 oral squamous cell carcinoma (OSCC)? - A retrospective analysis},
journal = {Oral and Maxillofacial Surgery},
year = {2026},
doi = {10.1007/s10006-026-01654-1}
}
EUVIMED